Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction
- PMID: 21127708
- PMCID: PMC2992873
- DOI: 10.1155/2011/739751
Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction
Abstract
The aim of this study was to investigate whether the VKORC1*3 (rs7294/9041 G > A), VKORC1*4 (rs17708472/6009 C > T), and CYP4F2 (rs2108622/1347 C > T) polymorphisms were associated with elevated warfarin maintenance dose requirements in patients with myocardial infarction (n = 105) from the Warfarin Aspirin Reinfarction Study (WARIS-II). We found significant associations between elevated warfarin dose requirements and VKORC1*3 and VKORC1*4 polymorphisms (P = .001 and P = .004, resp.), whereas CYP4F2 (1347 C > T) showed a weak association on higher warfarin dose requirements (P = .09). However, analysing these variant alleles in a regression analysis together with our previously reported data on VKORC1*2, CYP2C9*2 and CYP2C9*3 polymorphisms, gave no significant associations for neither VKORC1*3, VKORC1*4 nor CYP4F2 (1347 C > T). In conclusion, in patients with myocardial infarction, the individual contribution to warfarin dose requirements from VKORC1*3, VKORC1*4, and CYP4F2 (1347 C > T) polymorphisms was negligible. Our results indicate that pharmacogenetic testing for VKORC1*2, CYP2C9*2 and CYP2C9*3 is more informative regarding warfarin dose requirements than testing for VKORC1*3, VKORC1*4, and CYP4F2 (1347 C > T) polymorphisms.
Figures


Similar articles
-
CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.Br J Clin Pharmacol. 2010 Aug;70(2):234-40. doi: 10.1111/j.1365-2125.2010.03698.x. Br J Clin Pharmacol. 2010. PMID: 20653676 Free PMC article.
-
Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.Basic Clin Pharmacol Toxicol. 2013 Mar;112(3):209-14. doi: 10.1111/bcpt.12024. Epub 2012 Dec 6. Basic Clin Pharmacol Toxicol. 2013. PMID: 23061746 Clinical Trial.
-
Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.J Thromb Thrombolysis. 2012 Jul;34(1):120-5. doi: 10.1007/s11239-012-0725-7. J Thromb Thrombolysis. 2012. PMID: 22528326 Clinical Trial.
-
CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis.Pharmacogenomics J. 2020 Apr;20(2):306-319. doi: 10.1038/s41397-019-0117-x. Epub 2019 Nov 1. Pharmacogenomics J. 2020. PMID: 31673144
-
Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.Thromb Res. 2007;120(1):1-10. doi: 10.1016/j.thromres.2006.10.021. Epub 2006 Dec 11. Thromb Res. 2007. PMID: 17161452 Review.
Cited by
-
Cardiovascular Pharmacogenomics: Does It Matter If You're Black or White?Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:577-603. doi: 10.1146/annurev-pharmtox-010818-021154. Epub 2018 Oct 8. Annu Rev Pharmacol Toxicol. 2019. PMID: 30296897 Free PMC article. Review.
-
Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Curr Opin Cardiol. 2013 May;28(3):305-14. doi: 10.1097/HCO.0b013e32835f0bbc. Curr Opin Cardiol. 2013. PMID: 23478884 Free PMC article. Review.
-
Pharmacodynamic Modeling of Warfarin Dosing Algorithm for Cardiovascular Patients in Indonesia: A Tailored Method to Anticoagulation Therapy.Drug Des Devel Ther. 2025 Jan 29;19:671-681. doi: 10.2147/DDDT.S497738. eCollection 2025. Drug Des Devel Ther. 2025. PMID: 39896937 Free PMC article.
-
Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis.Meta Gene. 2016 Jul 5;9:197-209. doi: 10.1016/j.mgene.2016.07.002. eCollection 2016 Sep. Meta Gene. 2016. PMID: 27617219 Free PMC article. Review.
-
Cardiovascular pharmacogenomics.Circ Res. 2011 Sep 16;109(7):807-20. doi: 10.1161/CIRCRESAHA.110.230995. Circ Res. 2011. PMID: 21921273 Free PMC article. Review.
References
-
- Drapkin A, Merskey C. Anticoagulant therapy after acute myocardial infarction. Relation of therapeutic benefit to patient’s age, sex, and severity of infarction. Journal of the American Medical Association. 1972;222(5):541–548. - PubMed
-
- Aithal GP, Day CP, Kesteven PJL, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. The Lancet. 1999;353(9154):717–719. - PubMed
-
- D’Andrea G, D’Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005;105(2):645–649. - PubMed
-
- Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. The New England Journal of Medicine. 2005;352(22):2285–2293. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases